WO2022254414A2 - Composition nutraceutique ou pharmaceutique destinée à être utilisée dans le traitement et/ou la prévention d'états ou de maladies caractérisés par une déficience en magnésium - Google Patents

Composition nutraceutique ou pharmaceutique destinée à être utilisée dans le traitement et/ou la prévention d'états ou de maladies caractérisés par une déficience en magnésium Download PDF

Info

Publication number
WO2022254414A2
WO2022254414A2 PCT/IB2022/055491 IB2022055491W WO2022254414A2 WO 2022254414 A2 WO2022254414 A2 WO 2022254414A2 IB 2022055491 W IB2022055491 W IB 2022055491W WO 2022254414 A2 WO2022254414 A2 WO 2022254414A2
Authority
WO
WIPO (PCT)
Prior art keywords
magnesium
pharmaceutical composition
nutraceutical
starch
composition
Prior art date
Application number
PCT/IB2022/055491
Other languages
English (en)
Other versions
WO2022254414A3 (fr
Inventor
Umberto DI MAIO
Original Assignee
Neilos S.r.l.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neilos S.r.l. filed Critical Neilos S.r.l.
Priority to ES202390217A priority Critical patent/ES2963727R1/es
Publication of WO2022254414A2 publication Critical patent/WO2022254414A2/fr
Publication of WO2022254414A3 publication Critical patent/WO2022254414A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Definitions

  • the present invention relates a nutraceutical or pharmaceutical composition of substances effective in the prevention and/or treatment of conditions and diseases characterized by magnesium deficiency.
  • Magnesium is one of the seven most abundant elements in the Earth's crust and in our organism it represents the second cation most present in the intracellular environment.
  • the human body contains approximatively 25 g of magnesium which is required for the correct operation of about 300 enzymes. 90% of endogenous magnesium can be found in the muscles and bones, on the contrary in the blood it is mainly bound to albumin.
  • This element carries out in our organism different biological functions thereamong the maintenance of the ionic gradients, it contributes to the cellular and tissue integrity as well as to the DNA integrity, and to the synthesis of RNA and proteins.
  • Magnesium homeostasis is mainly controlled by the kidneys which determine an increased or reduced excretion via the urine in case of surplus or deficit.
  • the magnesium can be extracted from the reserves existing in bones, therefore the magnesium deficiency can predispose to osteopenia, osteoporosis and fractures.
  • hypomagnesemia is a relatively common condition in the clinical practice but which often is not easily recognized since few physicians evaluate the serum levels of such element which, besides, are not by themselves correctly predictive of a possible deficiency.
  • magnesium deficit can be found in approximately 84% of post-menopausal women having osteoporosis, in 11% of patients with chronic obstructions of respiratory tracts, in 80% of patients with hypertension treated for at least 6 months with hydrochlorothiazide or a single non-diuretic drug.
  • the optimum serum levels of magnesium are comprised between 0.75 and 0.95 mmol/L whereas upper levels could be index of hypermagnesemia; the reference nutritional value is 375 mg per day.
  • the chronic magnesium deficiency can lead to serious damages for our organism by involving the onset of hypertension, arrhythmia, calcification, atherosclerosis, thrombosis, heart attack, ictus, neurological disorders.
  • Magnesium deficiency can be due to different conditions such as: reduced intake with diet, reduced absorption due to intestinal pathologies, deficiency of vitamin D or use of drugs as pump inhibitors; excessive elimination due to the use of laxatives or diarrhoea; increased renal excretion due to diabetes, alcoholism, drug abuse; excessive sweating; increased need such as during pregnancy or under stress conditions.
  • magnesium oxide magnesium sulphate, magnesium chloride, magnesium carbonate known for having a high content of the element but a poor bioavailability due to their low solubility.
  • the organic sources of magnesium such as citrate, glutamate, orotate, lactate, gluconate, glycerophosphate are most appreciated and used in the market. Such salts have a lower magnesium yield but have a better solubility which determines a greater bioavailability and magnesium absorption.
  • the magnesium citrate is one of the salts most used in the products for the integration of magnesium.
  • magnesium salt is a more assimilable source than the inorganic forms (magnesium oxide) but which however has not a bioavailability so as to allow the optimum therapeutic effectiveness.
  • nutraceutical or pharmaceutical composition containing magnesium citrate as active principle which is provided with the features of gastro- resistance and high intestinal permeability with respect to the other traditional pharmaceutical forms present on the market.
  • nutraceutical or pharmaceutical composition characterized in that it comprises magnesium citrate as active principle and a combination of three functional excipients that is phosphatidylserine, phosphatidylcholine and starch, capable of providing gastro-resistance property, increasing the intestinal permeability and increasing the magnesium bio-availability.
  • the nutraceutical or pharmaceutical composition of the invention is particularly effective in the treatment and prevention of conditions and diseases, including the related symptomatic states, caused by magnesium deficiency.
  • the magnesium deficiency can be due to a reduced intake with diet or to an increased need.
  • a pharmaceutical product or a food supplement comprising the nutraceutical or pharmaceutical composition according to the invention fall within the invention too.
  • the pharmaceutical product or food supplement of the invention can optionally include additional active principles and functional excipients, which are easily selected by the person skilled in the art based upon the case needs. Even the selection of the carriers, excipients and/or diluents required for the formulation of the pharmaceutical product or food supplement in a suitable dosage form falls within the normal capabilities of the person skilled in the art.
  • nutraceutical or pharmaceutical composition according to the invention is defined in the enclosed claim 1.
  • the nutraceutical or pharmaceutical composition of the present invention comprises magnesium citrate as active principle and a combination of functional excipients which provide to the composition gastro-resistance propriety, increased intestinal permeability and increase the magnesium bioavailability.
  • Such combination of functional excipients includes phosphatidylcholine, phosphatidylserine and starch.
  • the nutraceutical or pharmaceutical composition of the invention then is particularly effective for carrying and adding magnesium in contrasting the typical symptoms of the magnesium deficiency states and for providing high levels of such element in periods of reduced intake with diet or of increased need for magnesium.
  • Examples of such conditions and diseases are weakness, tremors, muscle fasciculation, arrhythmia, depression, anxiety, psychosis, pregnancy.
  • the starch is an organic compound of polysaccharide nature consisting of the repetition of glucose units bound by -glycosidic bonds. It consists of two types of polymers: amylose, which generally is about 20%, and amylopectin, which generally is about 80%. Amylose forms the central part of the starch granules, it is soluble in very hot water and it consists of glucose molecules bound by oi-1,4 glycosidic bonds. Amylopectin is a polymer with a high branching level which forms the external part of the granules. The monomer units composing it are joined, in the branching points, by -1,6 glycosidic bonds. In nature it forms in the green portions of plants, to be then accumulated in the reserve organs, such as tubers, seeds and roots. For its properties and features, it has always had several industrial uses.
  • the starch is particularly important in the food industry, which uses it as thickening agent and in the production of sweeteners such as maltitol and sorbitol. Thanks to its adhesive properties it is also used in the production of paper and glues, under the form of starch solder. In the pharmaceutical industry the starch has been always used as excipient and for forming coatings, thanks to its binding properties .
  • modified starches that is starch molecules suitably modified to meet the needs of the various productive processes in which the starch is used.
  • modified starches can be obtained by using as source plants which underwent natural or induced genetic mutations and which then produce starches with the altered features.
  • Another strategy is that of modifying the starch, generally deriving from maize, tapioca and rice, by means of chemical treatments (addition of functional groups, treatment with acids and bases), physical treatments (gelatinization) or enzymatic treatments (partial hydrolysis).
  • Dextrins are an example of modified starches obtained by hydrolysis and repolymerization. Such reactions can be implemented by simple thermal degradation or by acid catalysis. The result is the obtainment of molecules characterized by shorter chains and then partially or totally soluble in water. Examples of dextrins are cyclodextrins and maltodextrins, excipients much used in nutraceutical and pharmaceutical field.
  • HAS high amylose starch
  • a starch in order to be defined as such, must have a percentage of amylose equal to at least 50%.
  • the high amylose starch can be obtained from genetically modified plants or by enriching with amylose starches having low percentages thereof.
  • the strategies used by different firms provide the use of HAS for the preparation of solid pharmaceutical forms or in the coating processes.
  • HAS have several advantages with respect to other types of starch, for example a better consistency, a greater thermal stability and a greater resistance to humidity and to the adhesion phenomena. Different strategies were implemented to exploit HAS advantages in the most suitable way.
  • starch different types can be used.
  • a starch of chemically not modified pregelatinized maize or a starch of pregelatinized acetylated maize with a high content of amylose which, in the specific case, can reach up to 90% by weight.
  • the percentage of acetylic groups is comprised between 0.5% and 2.5%.
  • Acetylation is performed with acetic anhydride which guarantees to reach a percentage of acetylic groups higher than 0.5% but not higher than 2.5%.
  • the starch pregelatinization treatment consists in dispersing the acetylated starch in water and in submitting the so-obtained dispersion to temperatures comprised between 100 and 130 degrees and to high pressures.
  • the starch granules submitted to such procedure explode and form a gel with a humidity content comprised between 5 and 10%.
  • the so-obtained modified starch can be used in the processes for coating hard and soft capsules and micro-granules and it guarantees to obtain a coating which results to be resistant and adequately viscous at the same time, which is capable of masking unpleasant smells and tastes and which can be used even when one wants to obtain a gastro-resistant or modified release pharmaceutical form.
  • the features of the pharmaceutical form can be modulated by modifying the amount of starch used in the coating.
  • Tests performed by using the above-mentioned starch showed the gastro-resistant action, the action of protecting from humidity and the capability of releasing the active principle in intestinal environment after few minutes.
  • phosphatidylcholine and phosphatidylserine are molecules structurally very similar to triglycerides. They are composed of one molecule of glycerol esterified in position 1 and 2 with fatty acids.
  • the fatty acids entering the composition of the natural phospholipids can have a length comprised between 12 and 22 carbon atoms; in position 1, generally, a saturated fatty acid is present, in position 2 there are unsaturated fatty acids; in position 3 a phosphate group is present which, in turn, is esterified with a complex molecule of various nature such as colin, serin, ethanolamine or inositol.
  • Such molecules are those providing the name to the phospholipid (phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine and phosphatidylinositol ) and influence the physical properties thereof since they establish if the molecule is anionic (like phosphatidylserine) or zwitterionic (like phosphatidylcholine) .
  • the peculiar chemical structure makes the phospholipids amphiphilic molecules, that is molecules capable of interacting both with polar solvents and with non polar solvents.
  • the carbonaceous chains of the fatty acids represent the non-polar portion which interacts with the non-polar solvents
  • the head of the phospholipid constituted by the phosphate group and by the molecule bound thereto, represents the polar portion interacting with water and the other polar solvents.
  • micellar critic concentration molecules with surfactant properties which above a certain temperature, called micellar critic concentration, aggregate by forming characteristic complexes which can vary by shape and size depending upon the conditions of the environment in which they form and upon the length of the chains of the fatty acids composing them. For example, if dispersed in aqueous solution, they form micelles with typical shape, with the polar heads facing outside towards the aqueous environment and the hydrophobic tails facing towards inside.
  • the phospholipids are molecules with a very important biological significance, in the first place since they participate in the composition of the biological membranes and, in the second place, since they are involved in different complex mechanisms such as the transduction of the intracellular signals, the adjustment of the intracellular concentration of some ions and the mediation of the inflammatory processes since they are sources of arachidonic acid.
  • the phospholipids are interesting molecules even from the technological point of view and, therefore, they are used in pharmaceutical and nutraceutical field as technological adjuvants in the formulation of carrying systems for several active principles. Many active principles, in fact, can have a poor bioavailability caused by the difficulty in crossing the barriers and the biological membranes of many body districts.
  • Phospholipids and in particular phosphatidylcholine and phosphatidylserine, represent a valid help in the field of the technological strategies for releasing various active principles.
  • One of the advantages of the carrying systems based upon phospholipids consists in the compatibility of the phospholipids with the cellular membranes, both at mucosal level and at the skin level.
  • Phosphatidylcholine and phosphatidylserine act as enhancers of intestinal and topic absorption and such action can be ascribed to the following action mechanisms: thanks to their properties and to their structure, they can melt with the lipids of the stratum corneum and of the membranes and can perturb the structure thereof by allowing the passage of various substances; in contact with the intestinal fluids they form micelles which contribute to increase the absorption of the active principles of interest since they extract the lipids from the membranes and alter the rheological properties, fluidity and composition of the membranes by increasing permeability; the above-mentioned micelles protect the active principles from chemical and enzymatic degradation and can be absorbed in the enterohepatic circle of the bile salts, together with the mixed micelles of diet, and be transported in the bloodstream where they release the incorporated active principles.
  • the present invention then allows to obtain:
  • the present invention constitutes a ready and valid intervention to contrast the typical symptoms of the magnesium deficiency states and to provide adequate levels of such element in periods of reduced intake with diet or of increased need. Such effect is ascribed to the combined action of the substances constituting it.
  • the starch used in the present invention allows to improve the organoleptic features and to stabilize the formulated compound, as well as to protect magnesium from stomach acid pH, by guaranteeing the release thereof at intestinal level.
  • Phosphatidylcholine and phosphatidylserine increase magnesium bioavailability thanks to the multi mechanism action at the level of the intestinal mucosa.
  • a breaking-down test is performed, as prescribed by Pharmacopeia.
  • a sample of the pharmaceutical form to be tested is placed in suitable instrument containing hydrochloric acid 0.1 N.
  • the gastro-resistant pharmaceutical form in contact with buffer at pH 2 for two hours, does not undergo breaking-down. Subsequently, the sample is transferred into a buffer at pH 6.8 in which it breaks-down within ten minutes.
  • the gastro-resistance can be evaluated even by means of dissolution test by Pharmacopeia according thereto the pharmaceutical form is put in contact with a solution 0.1 N of hydrochloric acid and to meet the essay it has to release a magnesium amount lower than 20% after 2 hours.
  • the cells kept in culture, are prepared by using a suitable growth medium (for example containing FBS, fetal bovine serum) and kept under controlled conditions (for example of 37°C, in an atmosphere having 5% of CO 2 and 100% of humidity). After several passages the cells are washed and pre- incubated with PBS. After the treatment with the formulations of interest the collected samples are subjected to analysis to quantify the magnesium.
  • a suitable growth medium for example containing FBS, fetal bovine serum
  • controlled conditions for example of 37°C, in an atmosphere having 5% of CO 2 and 100% of humidity
  • a variant discussed by way of example of the above-mentioned in vitro test provides the Caco-2 cells, incubated under the same conditions of temperature, CO 2 and humidity. After sucking the medium, the cells are washed twice with suitable buffer (for example 50 mM HEPES, 130 mM NaCl, 10 mM KC1, 5 mM glucose, 1 mM MgS0 4 , pH 7) and, subsequently, treated with the samples to be tested for one hour. At the end of the treatment, the monolayer of cells is washed with a buffer which removes magnesium and it is dissolved in suitable medium (for example 2% Triton-X) to be sonicated.
  • suitable buffer for example 50 mM HEPES, 130 mM NaCl, 10 mM KC1, 5 mM glucose, 1 mM MgS0 4 , pH 7
  • suitable medium for example 2% Triton-X
  • TEER epithelial electric resistance
  • the solution containing the composition the present invention relates to is subjected to a gastric and intestinal digestion and it is then applied (at the concentrations selected based upon the results of the preliminary cytotoxicity) on the apical side of the transwell (which in the model represents the intestinal lumen). At the pre-established time intervals (for example after 1-2-3-4 hours) on the baso-lateral side the liquid is collected, which will be subsequently analysed for the magnesium dosage by ICP or other analytical method accredited or known to the person skilled in the art.
  • the effectiveness of the present invention can be evaluated even by means an in vivo test on experimental animals in line with the directives of the European Community and of the Ministry of Health and approved by an Ethics Committee.
  • the test is performed for example on male mice Sprague-Dawley having an average weight of about 250-300 g.
  • the magnesium levels are measured by means of suitable analytical techniques on samples of blood or urine collected at time zero and at determined time intervals after the administration of the formulations .
  • the effectiveness of the present invention can be evaluated by means of suitable ex-vivo model for example in rat model according to the regulations for the animal welfare.
  • the intestinal mucosa is isolated.
  • the first fasting tract is removed and cut in sections; for each section the lumen content is removed without eliminating the muscle layer.
  • the absorption is expressed as amount of magnesium which permeates through the intestine sections in a model with acceptor and donor compartment after having simulated the gastric digestion process for the formulations to be tested and for the control.
  • the effectiveness of the composition the present invention relates to can be evaluated even by means of clinical study on man by monitoring after a determined time period how the blood or urine and magnesium levels vary before and after administration of the formulation the present invention relates to.
  • the nutraceutical or pharmaceutical composition of the present invention is particularly effective in contrasting the magnesium deficiency states thanks to the synergic action of its components.
  • the nutraceutical or pharmaceutical composition of the present invention is inserted inside a pharmaceutical product or a food supplement, which is formulated in a suitable dosage form, the composition and preparation thereof lies within the capabilities of the person skilled in the art.
  • the magnesium citrate in the nutraceutical or pharmaceutical composition of the invention is present in an amount comprised between 0.1 and 99%, preferably between 1 and 97%, still more preferably between 5 and 93%, with respect to the total weight of the composition.
  • additional percentages of magnesium citrate usable in the composition of the invention are: 2%, 3%, 4%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 75%, 80%, 85%, 90%, 95%, 99%.
  • the starch in the nutraceutical or pharmaceutical composition of the invention is present in an amount comprised between 0.1 and 90%, preferably between 1 and 80%, still more preferably between 4 and 70% with respect to the total weight of the composition.
  • additional percentages of starch usable in the composition of the invention are: 2%, 3%, 4%, 6%, 7%, 8%, 9%, 10%, 15%, 20%,
  • phosphatidylcholine in the nutraceutical or pharmaceutical composition of the invention is present in an amount comprised between 0.01 and 50%, preferably between 0.05 and 30%, still more preferably between 0.1 and 10% with respect to the total weight of the composition.
  • additional percentages of phosphatidylcholine usable in the composition of the invention are: 0.02%, 0.03%, 0.04%, 0.06%, 0.07%, 0.08%, 0.09%, 0.2%, 0.3%, 0.4%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 15%, 20%, 25%, 35%, 40%, or 45%.
  • phosphatidylserine in the nutraceutical or pharmaceutical composition of the invention is present in an amount comprised between 0.01 and 50%, preferably between 0.05 and 30%, still more preferably between 0.1 and 10% with respect to the total weight of the composition.
  • additional percentages of phosphatidylserine usable in the composition of the invention are: 0.02%, 0.03%, 0.04%, 0.06%, 0.07%, 0.08%, 0.09%, 0.2%, 0.3%, 0.4%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 15%, 20%, 25%, 35%, 40%, or 45%.
  • the pharmaceutical product or food supplement which comprises the pharmaceutical or nutraceutical composition of the invention, is formulated in a preferably oral pharmaceutical form, which can be solid, semi-solid or liquid.
  • a powder an oral soluble powder, a granulate, a hard capsule, a soft-gel capsule, a tablet, a sachet, a solution, a suspension or an emulsion can be mentioned.
  • nutraceutical or pharmaceutical compositions are formulated as pharmaceutical products or food supplements and administered in a suitable oral dosage form, in case divided into one or more dosage units, such as, for example, a capsule, a tablet or a sachet containing powder or granulate.
  • the present invention relates to it is possible to use the fluid bed granulation technology.
  • a preparation example is provided, applied to the compositions of the Examples 1 and 2.
  • the processing process consists in the following steps of: a) Mixing:
  • the raw materials previously charged in the granulator basket are subjected to a first fluid bed mixing step, with process air having a temperature of about 80-90°C, until obtaining a mixture having an average temperature of about 50°C.
  • a first fluid bed mixing step with process air having a temperature of about 80-90°C, until obtaining a mixture having an average temperature of about 50°C.
  • process air having a temperature of about 80-90°C
  • process air having a temperature of about 80-90°C
  • the granulation step provides the insertion of an aqueous solution of a suitably selected binding or granulation agent, by means of direct nebulization on the fluid bed premixed and fluidified bulk. Even in this step process air at 90°C is used by selecting suitably the speed for inserting the binding solution to obtain a granular structured according to expectations (granulometry, bulk density, smoothness) and homogeneous. c) Drying
  • the water content of the preformed granular is basically brought back to the conditions of the mixture of the starting raw materials.
  • the temperature of the process air of the granulate at the end of the step is suitably evaluated during pilot tests in function of such objective .
  • the semi-manufactured product obtained from the previous step is transferred from the fluid bed granulator to a swinging granulator where it is calibrated through a sieve for reducing the particle size of the granules and of the agglomerates with rougher structure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition de substances efficace dans la prévention et/ou le traitement d'états et de maladies caractérisés par une déficience en magnésium. La composition de l'invention comprend du citrate de magnésium, de la phosphatidylsérine, de la phosphatidylcholine et de l'amidon. Une telle formulation fournit à la composition des propriétés de gastro-résistance, de perméabilité intestinale accrue et de biodisponibilité élevée du principe actif du citrate de magnésium. La composition de l'invention est préparée sous forme posologique pharmaceutique solide, semi-solide ou liquide, de préférence pour une administration orale.
PCT/IB2022/055491 2021-06-04 2022-06-14 Composition nutraceutique ou pharmaceutique destinée à être utilisée dans le traitement et/ou la prévention d'états ou de maladies caractérisés par une déficience en magnésium WO2022254414A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES202390217A ES2963727R1 (es) 2021-06-04 2022-06-14 Composición nutracéutica o farmacéutica para su uso en el tratamiento y/o prevención de condiciones o patologías caracterizadas por deficiencia de magnesio

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102021000014504A IT202100014504A1 (it) 2021-06-04 2021-06-04 “Composizione nutraceutica o farmaceutica per l’uso nel trattamento e/o nella prevenzione di condizioni o patologie caratterizzate da carenza di magnesio”
IT102021000014504 2021-06-04

Publications (2)

Publication Number Publication Date
WO2022254414A2 true WO2022254414A2 (fr) 2022-12-08
WO2022254414A3 WO2022254414A3 (fr) 2023-11-23

Family

ID=77801811

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/055491 WO2022254414A2 (fr) 2021-06-04 2022-06-14 Composition nutraceutique ou pharmaceutique destinée à être utilisée dans le traitement et/ou la prévention d'états ou de maladies caractérisés par une déficience en magnésium

Country Status (3)

Country Link
ES (1) ES2963727R1 (fr)
IT (1) IT202100014504A1 (fr)
WO (1) WO2022254414A2 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1318597B1 (it) * 2000-06-23 2003-08-27 A C R Applied Coating Res S A Uso di un amido ad alto contenuto di amilosio acetilato epregelatinizzato.
IT201800006288A1 (it) * 2018-06-13 2019-12-13 Composizioni comprendenti minerali sucrosomiali contenenti sali minerali per uso nelle condizioni di deficienza di tali minerali
IT201900021564A1 (it) * 2019-11-19 2021-05-19 Neilos S R L Composizione nutraceutica o farmaceutica comprendente ferro pirofosfato per l’uso nel trattamento e/o nella prevenzione di condizioni o patologie caratterizzate da carenza di ferro

Also Published As

Publication number Publication date
IT202100014504A1 (it) 2022-12-04
ES2963727A2 (es) 2024-04-01
WO2022254414A3 (fr) 2023-11-23
ES2963727R1 (es) 2024-05-07

Similar Documents

Publication Publication Date Title
CN101951790B (zh) 一种含有一种核苷酸和/或一种核苷及一种掩味剂的适口的营养组合物
KR100210895B1 (ko) 생체부착성 약제학적 제형의 제조방법 및 이에 따라 제조된 제형
US20230000907A1 (en) Nutraceutical or pharmaceutical composition comprising iron pyrophosphate for treating and/or preventing iron deficiency conditions or diseases
BR122022015143B1 (pt) Método para preparar uma composição sólida à base de ferro
CN109090443A (zh) 一种具有锁钙补钙强骨功能的营养配方产品
JP2019509345A (ja) フェニル酪酸ナトリウムを含む口当たりの良い組成物及びその使用
CN106307553A (zh) 一种含hmb的大豆肽蛋白质粉及其制备方法
WO2022254414A2 (fr) Composition nutraceutique ou pharmaceutique destinée à être utilisée dans le traitement et/ou la prévention d'états ou de maladies caractérisés par une déficience en magnésium
CA2645574C (fr) Medicament servant a guerir l'hyperphosphatemie, et sa preparation
CN105682481A (zh) 包含胆碱及其衍生物的组合物、其用途以及其制备方法
JP3981991B2 (ja) 水性乳化栄養組成物及びその用途
JP2023505246A (ja) 無機物および／またはビタミンならびに多糖を含む製剤、その組成物ならびに前記無機物および／またはビタミンの補充におけるその使用
DK2461701T3 (en) Food formulation comprising glycogen
WO2022118274A1 (fr) Compositions destinées à être utilisées dans le traitement et/ou la prévention d'états ou de maladies de carence en fer
CN110787143A (zh) 一种盐酸二甲双胍片剂及其应用
WO2019239372A1 (fr) Composition comprenant des minéraux de sucrosomial contenant des sels minéraux destinée à être utilisée dans des états de carence en de tels minéraux
US20240122965A1 (en) pH-RESPONSIVE HYDROGEL AND MANUFACTURING METHOD THEREOF
OA20752A (en) Formulations comprising a mineral and/or a vitamin and a polysaccharide, compositions thereof and use thereof in supplementing said mineral and/or vitamin.
EP1043022B1 (fr) Inhibiteurs d'absorption d'ions sodium et agents pour accelerer l'excretion d'ions sodium en tant qu'agents actifs pour prevenir et traiter les maladies provoquees par une absorption excessive de chlorure de sodium
WO1998008877A1 (fr) Derives de chitosane, procedes permettant de produire ceux-ci et leur utilisation
González Bermúdez Anti-regurgitation infant formulas: in-vitro study about the effect of different thickering ingredients on their physicochemical characteristics across a digstive process, mineral availability and infant microbiota
CN117919212A (zh) 一种具有抗肥胖功效的多肽组合物及其应用
EP4326249A1 (fr) Compositions pharmaceutiques et méthodes de traitement de l'hypertension
WO2023166413A1 (fr) Composition nutraceutique ou pharmaceutique contenant un extrait de levure de riz rouge
WO2024010628A1 (fr) Compositions pharmaceutiques et méthodes de traitement de l'hypertension

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22736368

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: P202390217

Country of ref document: ES

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22736368

Country of ref document: EP

Kind code of ref document: A2